Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Unattributed VC | Alive

Total Raised


Last Raised

$2.03M | 4 yrs ago

About Light Sciences Oncology

Light Sciences Oncology (LSO) is developing Talaporfin Sodium for solid tumors as well as other indications such as BPH. Talaporfin Sodium is a water-soluble drug targeted by a small, single-use, disposable drug activator included with the drug. Talaporfin Sodium is designed to provide tolerable, effective, and repeatable treatments for patients. LSO has completed treatment of patients in a Phase 3 trial of Talaporfin Soduim in hepatocellular carcinoma (HCC), a Phase 3 trial for metastatic colorectal cancer (MCRC) and in Phase 1 and Phase 2 clinical trials in benign prostatic hyperplasia (BPH), or enlargement of the prostate.

Light Sciences Oncology Headquarters Location

12600 SE 38th Street Suite 111

Bellevue, Washington, 98006,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Light Sciences Oncology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Light Sciences Oncology is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Light Sciences Oncology Patents

Light Sciences Oncology has filed 13 patents.

The 3 most popular patent topics include:

  • Alpha blockers
  • Antiandrogens
  • Male genital surgery
patents chart

Application Date

Grant Date


Related Topics




Vascular diseases, Cardiology, Transcription factors, Implants (medicine), Interventional radiology


Application Date


Grant Date



Related Topics

Vascular diseases, Cardiology, Transcription factors, Implants (medicine), Interventional radiology



Latest Light Sciences Oncology News

Lyman BioPharma Consulting LLC

May 14, 2018

Welcome to the Seattle Biotech Graveyard This page details the fates of a number of Seattle or NW based biotech companies that are no longer with us because they were acquired, merged, or folded: Acylin Therapeutics disappeared in 2014 after its assets were sold off to an unnamed pharma company Afya World Medicines merged into IDRI in 2008 Albany Molecular Research - Scientific services provider (based in NY) with labs in Bothell, WA closed down in 2012 and moved jobs to Singapore Alcide was bought out by Ecolab in 2004 Allozyne, a protein modification company, closed its doors in 2014 Alpine Biosciences was bought by Oncothyreon in Aug. 2014 Amgen is closing down its two facilities and pulling out of WA State in 2015 Anawah (Fred Hutch spinout) went out of business when? Amnis, maker of quantitative flow cytometry imaging systems, is being acquired by EMD Millipore in 2011 Amp Orthopedics appears to have gone out of business maybe in 2013? Archus Orthopedics ran out of money in September 2009 Argus Genetics LLC, a provider of dog breed DNA testing services, was spun out of the FHCRC and then sold their technology (Wisdom Panel MX) to Mars in 2005 Ascentia Biomedical Corp. did a reverse merger with Fortress Technology Systems in 2006 and changed its name to Duncan Technology Group Berlex, the US subsidiary of Schering AG, bought Immunex's Leukine in 2002 when Immunex was bought by Amgen. Berlex (as part of Schering AG) was then acquired by Bayer in 2006, who subsequently sold Leukine to Genzyme in 2009 Bristol Meyers Pharmaceutical Research Institute had a site in Seattle, but it was closed down in 1997 Blue Heron Biotechnology was acquired by OriGene Technologies in 2010 Calcionics was developing peptide therapeutics targeting calcification, but it appears to have gone out of business by 2012 Calypso Medical Technologies was acquired by Varian Medical Systems in Sept. 2011 Calistoga Pharmaceuticals was acquired by Gilead in 2011 Clarisonic, maker of the Clarisonic skin brush, was acquired by L’Oreal in 2011 CDR Therapeutics went out of business when? CellExCys (Fred Hutch spinout) went out of business when? Cellpro lost a patent lawsuit to Becton Dickinson in 1997. They were forced to divest their Ceprate column to BD, and then went under in 1998 Ceptyr was developing protein tyrosine phosphatase based drugs and went out of business CG Therapeutics, a cancer vaccine company, went out of business around 2012-2013 Columbia Northwest Pharmaceuticals (suicide prevention) shut down their website and likely went out of business in 2012 Combimatrix is shutting down its operations in Mukilteo in 2010 and moving to Irvine, CA to focus on diagnostics Confirma, Inc., a maker of computer-assisted detecting (CAD) technology for medical imaging was acquired by Merge Healthcare in 2009 Corixa was acquired by GlaxoSmithKline in 2006 Corus was acquired by Gilead Sciences in 2006 Cytopeia was purchased by Becton Dickinson in 2008 Darwin Molecular was acquired by Chiroscience in 1996. Chiroscience then merged with Celltech in 1999. Celltech was purchased by UCB in 2004 Dendreon went bankrupt in Nov. 2014 and was purchased by Valeant in Feb. 2015 for $495M Dharma Therapeutics was developing a needle free drug and vaccine delivery system, but they seem to have gone out of business Eden Bioscience Corp., an agricultural biotech, will be dissolved and liquidated in 2009 Elanex Pharmaceuticals went out of business Elixir Research - Dysphagia management system Emergent Detection, who was working on developing a personal fat burn manager, has gone out of business Enodar Biologics (Fred Hutch spinout) went out of business when? Epigenomics is closing down in Seattle and moving to the East coast in 2012 Epoch Pharmaceuticals merged into Nanogen in 2004 Fate Therapeutics - Stem cell based therapies moved HQ to CA shortly after being formed Generic Medical Devices website disappeared sometime in 2012 and they presumably are out of business Genetic Systems was acquired by Bristol Meyers in 1987 for $310M Geospiza made software for DNA analysis and lab management; acquired by Perkin Elmer 5-5-11 Glycostasis Inc. - Focused on a protein that binds and releases insulin; purchased by Eli Lilly in Feb. 2016 Groove Biopharma (formerly Mirina) - Uses microRNA to develop new drugs GPC-Rx (later named PharmSelex) was launched by Accelerator in 2008 and later shut down HemaQuest left Seattle in 2010 and moved to San Diego; it shuttered operations in early 2014 Homestead Clinical, another Accelerator company, folded in 200? Icos was acquired by Eli Lilly in 2006 for $2.2B ID Biomedical, a Vancouver BC based vaccine maker, had a manufacturing facility in Bothell; it was acquired by Glaxo Smith Kline in 2005 Ikaria - Focused on metabolic depression and critical care medicine, it was acquired by Mallinckrodt in April, 2015 ImaRxTherapeutics - Blood clot dissolving technology company that was acquired by Sycamore Films, Inc. in a reverse merger in 2010 Imre changed its focus and its name to Cypress Bioscience in 1996 and moved to San Diego, and was then bought out by Royalty Pharma in Jan. 2011 Immunex was acquired by Amgen in 2002 for $10B. It's first drug Leukine was sold off to Berlex in 2002; Berlex was later acquired by Bayer, and Bayer sold Leukine to Genzyme in March 2009 Indel Therapeutics worked on novel antibiotics and appears to have gone out of business when ? Innovative Pulmonary Solutions, a developer of treatments for COPD, moved to Minnesota in 2013 Inson Medical Systems, focused on biomedical drug delivery, appears to have gone out of business Kaleetan Pharmaceuticals, a vaccine focused startup, appears to have gone out of business Koronis was developing anti-viral drugs via viral decay methodologies but appears to have gone out of business LigoCyte Therapeutics of MT was acquired by Takeda in ??? Light Sciences was acquired by Light Sciences Oncology in 2006 Lumera had a microarray technology and transferred its assets to Plexera in 200? Luminary Medical Technologies was working on macular degeneration but appears to have gone out of business Mediquest Therapeutics website link was abandoned and presumably the company went out of business in 2012 Microsoft Amalga Life Sciences - Life sciences software business was sold off to Caridigm Molecumetics, a subsidiary of Tredegar Industries, went out of business in ??? Nanogen went bankrupt in 2009 Nastech changed its scientific focus away from nasal based drug deliver and spun off MDRNA in late 2007. MDRNA then combined with Cequent Pharmaceuticals of Cambridge in 2010 to form Marina Biotech - (formerly MDRNA) RNAi based company, ceased most operations as of 6-1-12 MitoGuard Neuroscience - Photobiomodulation device company apparently disappeared in 2012 Natural Molecular Testing Corporation went bankrupt in 2013 amidst fraud allegations and a Justice Department Criminial Investigation of its genetic testing program NeoRx changed its name to Poniard in 2006 and moved its HQ to CA. It appears to be out of business in 2015 NW Biotherapeutics - Dendritic cell based cancer vaccines started in Seattle, but moved to Bethesda Novo Nordisk - Branch of Danish pharma focusing on immunity research closed in 2014 Nura was acquired by Omeros in 2006 Oculon was acquired by Pharmos Corp. in 1995 Oncogen was acquired by Bristol Myers in 1986 OncoGenex was reverse merged out of existence by Achieve Life Sciences Inc. in Jan 2017 Otogene USA (Fred Hutch spinout) lasted from 1998-2002; some of its IP was used to start Sound Pharmaceuticals Pacific Bioscience Laboratories, maker of the Clarisonic skin care system; is being acquired in 2011 by L’Oreal USA PathoGenesis was acquired by Chiron/Novartis in 2000 for $660M Pathway Medical Technologies, maker of devices to treat arterial diseases, was acquired in 2011 by Bayer’s Medrad unit PharmSelex was an Accelerator company working on small molecule GPCR inhibitors that is now out of business Plexera Bioscience developed a surface plasmon resonance analysis system but was shut down by Lumera in 2008. Assets were sold to Plexera LLC in 2009, which continues to make a proteomic processor system but is no longer based in the NW Poniard (see NeoRx above) Pregenen (Precision Genome Engineering) was bought by bluebird bio in June 2014 Primal - Focus on G-protein coupled receptors; it was folded into Nura in 2004,which in turn was acquired by Omeros in 2006 ProCyte of Redmond WA was acquired by PhotoMedex in 2004 in a $24.4M stock swap Promentix was developing Alzheimer’s disease therapies, but was unable to raise capital and folded Rasiris - Montana company developing breast cancer drugs disappeared in ??? Receptagen Ltd became Spantel Communications in 2001 Receptech Corp. was spun out from Immunex as a SWORD company in 1989 and was then re-acquired in 1992 Recodagen was an Accelerator company that targeted mechanisms that allow cancer metastasis but went out of business Regulome started in 2001 went out of business sometime after 2003 Rhizogenics Corp. on Bainbridge went out of business Ricerca Biosciences, which had purchased MDS Pharma Services in March 2010; was purchased by Euofins Panlabs in 2012 (?) Rosetta Inpharmatics was closed down by Merck in 2009 Sarepta Therapeutics (formerly AVI BioPharma) - worked on RNA therapeutics for MD, restenosis, viruses; moved to Boston in Aug. 2012 Scolr Pharma, which worked on controlled drug delivery technology development, appears to have gone out of business in 2014 Seredigm was an Accelerator company studying the use of biologics for ischemia/reperfusion injury when it folded Sonosite, maker of handheld ultrasound scanners; is being acquired by and will be a wholly owned subsidiary of Fujifilm Sonos Pharmaceuticals merged with Canada’s OncoGenex Technologies to form Oncogenex in 2008 Spiration was acquired by Olympus in 2010 TapImmune was developing vaccines for oncology and infections, but it moved to Florida in Nov. 2015 Targeted Genetics merged with Biocontrol and changed its name and scientific focus to AmpliPhi Biosciences in 2011; HQ now in London Teranode Corp was acquired by Rage Frameworks in 2010 TherEpi Corporation - Epigenetic drug discovery focus company was either bought out or acquired Trubion accepted an acquisition offer by Emergent BioSolutions in August 2010; the acquisition closed Oct. 28, 2010 Vascular Reconditioning was acquired by Light Sciences Oncology in 2006 VieVax was an Accelerator company that folded in 200? Visient Therapeutics - Vision focused subsidiary of Light Sciences didn’t make it VizX's software product GeneSifter was sold off to Geospiza in 2008, and VizX shut down VLST shut down in 2013 without having advanced a single drug into clinical trials during 9 years; focused on finding new drug targets based on virus interactions Xcyte Therapies merged into Cyclacel in 2005 Xori was sold sometime after it graduated from Accelerator in 2011 ZetaRx was folded into Juno Therapeutics when it launched in 2014 ZymoGenetics accepted an acquisition offer by Bristol-Myers Squibb in September 2010 and is no longer an independent company; the deal closed Oct. 12, 2010 © 2006 - 2018 Lyman BioPharma Consulting LLC Contact Me

  • When was Light Sciences Oncology founded?

    Light Sciences Oncology was founded in 1994.

  • Where is Light Sciences Oncology's headquarters?

    Light Sciences Oncology's headquarters is located at 12600 SE 38th Street, Bellevue.

  • What is Light Sciences Oncology's latest funding round?

    Light Sciences Oncology's latest funding round is Unattributed VC.

  • How much did Light Sciences Oncology raise?

    Light Sciences Oncology raised a total of $175.76M.

  • Who are the investors of Light Sciences Oncology?

    Investors of Light Sciences Oncology include New Science Ventures, Deephaven Capital Management, CDIB Capital Group, Novo Holdings, Scandinavian Life Science Venture and 13 more.

  • Who are Light Sciences Oncology's competitors?

    Competitors of Light Sciences Oncology include ALung Technologies, Mercator MedSystems, eNeura Therapeutics, DFine, Pathfinder Therapeutics and 10 more.

You May Also Like


CardioOptics is a developer of Trans-Blood Vision products to provide catheter-based direct visualization through blood using infrared light.

Novasys Medical

Novasys Medical, formerly Genesis Medical, is a medical device company that develops therapies in women's health. The company's initial focus is the development and commercialization of the Renessa System, a non-surgical approach to the treatment of female stress urinary incontinence (SUI).

eNeura Therapeutics

eNeura Therapeutics develops the use of portable, non-invasive Transcranial Magnetic Stimulation (TMS) devices for the treatment of migraines.

NAS Medical

NAS Medical develops, manufactures, and sells radiation therapy products for use in cancer treatment.

Pathfinder Therapeutics

Pathfinder Therapeutics (PTI) is the developer of Explorer, an image-guided "GPS" device that enables physicians to accurately and efficiently guide the delivery of cancer therapeutics (usually resection and/or ablation) in soft-tissue organs. Explorer is cleared by the FDA in the category of Intraoperative Soft Tissue Tracking. Scout, the company's advanced 3D planning software, provides highly detailed visual and volumetric information for preoperative assessment, thus enabling clinicians to visualize the site of disease, plan the resection and/or ablation and monitor the resultant effects.


Vascure is a medical device company. The company is developing an therapeutic device for percutaneous treatment of arterial disease. Vascure's system will offer a one-stop solution for restoring blood flow to narrowed or occluded blood vessels in a range of clinical conditions, including heavily calcified lesions. Vascure will provide Intervantionalists with a safe and easy to use device, shortening procedure time, allowing percutaneous treatment in cases previously requiring radical surgical procedures and generating improved clinical outcomes.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.